Why is Marksans Pharma falling/rising?

As of 18-Sep, Marksans Pharma Ltd is currently priced at 178.70, reflecting a decrease of 0.8 or 0.45%. The stock has recently underperformed its sector by 1.5% and has experienced a trend reversal, falling after three consecutive days of gains. In terms of returns, the stock has shown a 2.14% increase over the past week, but it has declined by 2.93% over the last month and has a year-to-date drop of 39.68%. Despite a high management efficiency indicated by a 17.66% ROE and a low debt-to-equity ratio, the company has faced challenges with poor long-term growth, as evidenced by a -0.29% annual growth rate in operating profit over the last five years. Additionally, the recent negative quarterly results, including a 38.7% drop in PAT, have contributed to the stock's decline.
In the broader market context, while the Sensex has increased by 1.80% over the past week, Marksans Pharma's performance has lagged behind, highlighting its struggles in comparison to the benchmark. The stock's year-long performance of -36.46% starkly contrasts with the market's slight decline of -1.96%, indicating significant underperformance. Although there is rising investor participation with a notable increase in delivery volume, the overall sentiment remains cautious due to the company's expensive valuation and low inventory turnover ratio. This combination of factors suggests that while there may be some positive indicators, the prevailing negative trends are driving the stock's current decline.